Specify a stock or a cryptocurrency in the search bar to get a summary
Arch Biopartners Inc
ACHFFArch Biopartners Inc., together with its subsidiaries, engages in the development of therapeutic drugs for inflammation and acute organ injuries in Canada. It focuses on developing its lead drug candidate LSALT Peptide, a product in Phase 2 clinical trials to treat dipeptidase-1 mediated organ inflammation in the lungs, liver, and kidneys. The company also develops AB569 for treating antibiotic-resistant bacterial infections, and for the treatment of wounds; and Borg, a peptide-solid surface interface to reduce corrosion of metals. Arch Biopartners Inc. is based in Toronto, Canada. Address: 27 Street Clair Avenue East, Toronto, ON, Canada, M4T 2M5
Analytics
WallStreet Target Price
3.5 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures ACHFF
Dividend Analytics ACHFF
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History ACHFF
Stock Valuation ACHFF
Financials ACHFF
Results | 2019 | Dynamics |